|
Perhexiline
resources
DRUG INFO
Perhexiline
Drug Name:
Perhexiline
|
|
|
Indication: For the management of severe angina pectoris
Pharmacology: Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.
Mechanism Of Action: Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization.
Drug Category: Vasodilator Agents; Cardiovascular Agents; ATC:C08EX02
Brand Names/Synonyms: CHEMBANK1158; PERHEXILINE; Perhexilene; Perhexilina [Inn-Spanish]; Perhexiline; Perhexilinum [Inn-Latin]; Perhexilline
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: 2-(2,2-dicyclohexylethyl)piperidine
Chemical Formula: C19H35N
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00107
CAS Registry Number: 6621-47-2
| | |
